7/102 sources · 2 publishersUpdated Oct 8, 19:41 UTC
Integra LifeSciences launches $600 million senior secured term loan B
Integra LifeSciences Holdings announced the launch of a proposed $600 million senior secured term loan B with a seven‑year maturity. The CFO said the financing will be used to refinance existing debt, pay fees and extend maturities, subject to market conditions and final pricing. Completion of the loan is expected to occur alongside a broader refinancing of the company’s capital structure.
Why it matters
The company expects the loan to refinance indebtedness, extend debt maturities and preserve financial flexibility, which could improve liquidity and reduce leverage for shareholders.
Key facts
- 1Integra LifeSciences announced a proposed $600 million senior secured term loan B. globenewswire.com
- 2The loan has a seven‑year term. globenewswire.com
- 3Proceeds will be used to refinance existing indebtedness and pay associated fees and expenses. globenewswire.com
- 4Lea Knight, Executive Vice President and Chief Financial Officer, said the transaction will extend maturities and maintain financial flexibility. globenewswire.com
- 5Final size, terms and pricing of the loan have not been determined and the transaction is subject to market and customary conditions. globenewswire.com
Open questions
- Final size, terms and pricing of the loan are not yet known.
- Completion depends on market and other customary conditions.
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.